GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cognetivity Neurosciences Ltd (OTCPK:CGNSF) » Definitions » Debt-to-EBITDA

Cognetivity Neurosciences (Cognetivity Neurosciences) Debt-to-EBITDA : -0.98 (As of Oct. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Cognetivity Neurosciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cognetivity Neurosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was $1.00 Mil. Cognetivity Neurosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was $1.00 Mil. Cognetivity Neurosciences's annualized EBITDA for the quarter that ended in Oct. 2023 was $-2.04 Mil. Cognetivity Neurosciences's annualized Debt-to-EBITDA for the quarter that ended in Oct. 2023 was -0.98.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cognetivity Neurosciences's Debt-to-EBITDA or its related term are showing as below:

CGNSF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.67   Med: -0.14   Max: -0.1
Current: -0.67

During the past 7 years, the highest Debt-to-EBITDA Ratio of Cognetivity Neurosciences was -0.10. The lowest was -0.67. And the median was -0.14.

CGNSF's Debt-to-EBITDA is ranked worse than
100% of 431 companies
in the Healthcare Providers & Services industry
Industry Median: 2.55 vs CGNSF: -0.67

Cognetivity Neurosciences Debt-to-EBITDA Historical Data

The historical data trend for Cognetivity Neurosciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognetivity Neurosciences Debt-to-EBITDA Chart

Cognetivity Neurosciences Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
Debt-to-EBITDA
Get a 7-Day Free Trial - -0.12 -0.17 -0.10 -0.20

Cognetivity Neurosciences Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.20 -0.20 -0.35 -0.45 -0.98

Competitive Comparison of Cognetivity Neurosciences's Debt-to-EBITDA

For the Health Information Services subindustry, Cognetivity Neurosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cognetivity Neurosciences's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cognetivity Neurosciences's Debt-to-EBITDA falls into.



Cognetivity Neurosciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cognetivity Neurosciences's Debt-to-EBITDA for the fiscal year that ended in Jan. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.962 + 0) / -4.755
=-0.20

Cognetivity Neurosciences's annualized Debt-to-EBITDA for the quarter that ended in Oct. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.998 + 0.998) / -2.044
=-0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Oct. 2023) EBITDA data.


Cognetivity Neurosciences  (OTCPK:CGNSF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Cognetivity Neurosciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cognetivity Neurosciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cognetivity Neurosciences (Cognetivity Neurosciences) Business Description

Traded in Other Exchanges
Address
800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.

Cognetivity Neurosciences (Cognetivity Neurosciences) Headlines

From GuruFocus

The Most Innovative Healthcare AI Developments of 2019

By ACCESSWIRE AccessWire 04-12-2019